Natera Inc NTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
-
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
-
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
-
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
-
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
-
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
-
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
-
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
Trading Information
- Previous Close Price
- $269.83
- Day Range
- $262.00–272.31
- 52-Week Range
- $131.81–288.04
- Bid/Ask
- $271.29 / $272.00
- Shares Outstanding
- 143.22M
- Market Cap
- $38.87B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 535.56
- Price/Sales
- 14.93
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 6,140
- Website
- https://www.natera.com
Valuation
|
Metric
|
NTRA
|
|---|---|
Price/Earnings (Normalized) | 535.56 |
Price/Book Value | 21.71 |
Price/Sales | 14.93 |
Price/Cash Flow | 164.38 |
Price/Earnings
NTRA
Financial Strength
|
Metric
|
NTRA
|
|---|---|
Quick Ratio | 2.70 |
Current Ratio | 2.96 |
Interest Coverage | −81.94 |
Quick Ratio
NTRA
Profitability
|
Metric
|
NTRA
|
|---|---|
Return on Assets (Normalized) | 3.28% |
Return on Equity (Normalized) | 4.68% |
Return on Invested Capital (Normalized) | 2.27% |
Return on Assets
NTRA
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|r&h<#Mq | LOCK|@? | $199B | |||
| Danaher Corp
DHR
| LOCK|d&#&t%fn | LOCK|Gdm | $142B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|^!$DYJ? | LOCK|KZs | $44B | |||
| Agilent Technologies Inc
A
| LOCK|CLpC<T^ | LOCK|#< | $38B | |||
| Waters Corp
WAT
| LOCK|#b?X^!Z | LOCK|Kh | $37B | |||
| IQVIA Holdings Inc
IQV
| LOCK|LN$$p% | LOCK|nPj? | $35B | |||
| Illumina Inc
ILMN
| LOCK|f>@>@! | LOCK|^V&G# | $28B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|%!$xs%g? | LOCK|^f#&h | $27B | |||
| Quest Diagnostics Inc
DGX
| LOCK|wxC$Bm | LOCK|sNr&l | $22B | |||
| Labcorp Holdings Inc
LH
| LOCK|>S<?&w^b | LOCK|?#K> | $22B |
United States